Plexin domain-containing 1 may be a biomarker of poor prognosis in hepatocellular carcinoma patients, may mediate immune evasion

Table 2 Univariate and multivariate Cox regression analysis of overall survival in 123 hepatocellular carcinoma patients

Variables	Overall survival		P value
	HR	95%CI
Univariate analysis
Age	1.320	0.753-2.315	0.332
Gender	0.972	0.678-1.395	0.878
Tumor size	1.168	0.666-2.049	0.588
AFP (ng/mL, ≤ 20/> 20)	1.397	0.771-2.532	0.270
Cirrhosis	2.474	1.376-4.449	0.002b
ALBI score	2.254	1.275-3.975	0.005b
APRI score	1.787	1.014-3.149	0.045a
HBV	0.487	0.217-1.089	0.080
PLXDC1 expression	2.714	1.524-4.832	0.001b
Multivariate analysis
Age	1.273	0.719-2.256	0.408
Gender	1.101	0.753-1.611	0.619
Tumor size	1.128	0.633-1.208	0.683
AFP (ng/mL, ≤ 20/> 20)	0.645	0.324-1.284	0.212
Cirrhosis	0.513	0.219-1.204	0.010a
ALBI score	2.384	1.384-4.217	0.003b
APRI score	1.941	1.096-3.435	0.023a
HBV	0.448	0.196-1.027	0.125
PLXDC1 expression	2.583	1.137-4.993	0.005b

^aP < 0.05.

^bP < 0.01.

CI: Confidence interval; HR: Hazard ratio; ALBI: Albumin-bilirubin; APRI: Aspartate aminotransferase to platelet ratio; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; PLXDC1: Plexin domain-containing 1.